RE:PR more partial responses form Adlay trial...These results have further added to ONCY's IND-213 two-arm study results which demonstrated that pelareorep is effective when added to the chemotherapy agent paciltaxel (and without the need for any other I/O agent) versus paclitaxel alone. - and that the addition of pelareprep was responsible for the partial and stable disease responses seen.
Any global regulatory authroity would consider these findings significant when considering pelareorep's effectiveness for marketing approval.